Sanofi (EPA: SAN)
France
· Delayed Price · Currency is EUR 99.02
+0.17 (0.17%)
Jan 21, 2025, 5:35 PM CET
Sanofi Revenue
Sanofi had revenue of 14.16B EUR in the quarter ending September 30, 2024, with 11.49% growth. This brings the company's revenue in the last twelve months to 48.45B, up 6.01% year-over-year. In the year 2023, Sanofi had annual revenue of 46.03B with 1.42% growth.
Revenue (ttm)
48.45B
Revenue Growth
+6.01%
P/S Ratio
2.56
Revenue / Employee
562.74K
Employees
86,088
Market Cap
123.56B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 46.03B | 644.00M | 1.42% |
| Dec 31, 2022 | 45.39B | 6.21B | 15.86% |
| Dec 31, 2021 | 39.18B | 1.81B | 4.83% |
| Dec 31, 2020 | 37.37B | -262.00M | -0.70% |
| Dec 31, 2019 | 37.63B | 1.95B | 5.48% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EssilorLuxottica Société anonyme | 25.83B |
| Sartorius Stedim Biotech | 2.74B |
| bioMérieux | 3.81B |
| Ipsen | 3.44B |
| Eurofins Scientific SE | 6.72B |
| Virbac | 1.34B |
| Ramsay Générale de Santé | 5.01B |
| emeis Société anonyme | 5.43B |
Sanofi News
- 13 hours ago - Sanofi receives GMP warning letter for Genzyme facility - Seeking Alpha
- 18 hours ago - Sanofi says FDA lifted clinical hold on trial for Cialis OTC switch - Seeking Alpha
- 1 day ago - Press Release: Opella reaches study milestone for Cialis - GlobeNewsWire
- 2 days ago - Top 4 Immunology Stocks Poised For Growth In 2025 - Seeking Alpha
- 7 days ago - Sanofi (SYN) CEO Paul Hudson Hosts 43rd Annual J.P. Morgan Healthcare (Transcript) - Seeking Alpha
- 8 days ago - Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025 - Seeking Alpha
- 8 days ago - Scribe Therapeutics Achieves Milestone for In Vivo Program in Collaboration with Sanofi - Business Wire
- 9 days ago - Press Release: Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma - GlobeNewsWire